Health 2.0 announces keynotes and preliminary program

11 - 12 May 2016, Barcelona, Spain.
Health 2.0 announces keynote speakers and preliminary program for the 7th Annual Health 2.0 Europe Conference. After a highly successful conference last May in Barcelona, the International event series will be back for another 3 full days discussing challenges faced by the healthcare system and showcasing the latest technologies and innovations that are making an impact.

Health 2.0 Europe is a truly international conference, bringing speakers from all across the world to discuss and find solutions to those healthcare challenges from a global perspective. It will bring together 600 digital health champions including entrepreneurs, executives, thoughtleaders, investors, physicians, and patients over insightful keynotes, interactive workshops, animated round tables and more than 50 rapid fire live demo.

The keynote speakers already confirmed are:

  • Esther Dyson, active business angel and board member in various healthcare companies, she was named by Forbes as one of the most powerful American business woman. She will share her vision on the healthcare challenges and how to tackle them.
  • Dr. Rafael Grossmann, the surgeon who practiced the 1 st live surgery using Google Glass will showcase exclusive innovative solutions he is using and that are supporting both healthcare professionals and enhancing patients' experience.
  • Damien Marmion, Global Head of Health at AXA, will share AXA’s vision as an insurance pioneer in reimbursing digital health solutions and the role of reimbursement in accelerating adoption of digital health in Europe.
  • Dr. Julio Mayol, chief medical and innovation officer at San Carlos Hospital in Madrid, will give his vision on how hospitals should look at health 2.0 solutions and present their successful Smart Health Lab, an initiative launched to design, develop and implement innovative solutions.
  • Pēteris Zilgalvis, Head of Unit for eHealth and Well Being in DG CONNECT, will share the vision and strategic plan of the European Commission on getting a more dynamic digital health ecosystem, involving every stakeholder.

Health 2.0 Europe takes into account all the different stakeholders of the digital health ecosystem. Some of the topics that we will be discussing this year:

  • Solutions for hospitals and healthcare professionals
  • Building a new framework for Health 2.0 adoption in the clinic setting
  • Building Blocks to a Dynamic Health 2.0 Ecosystem in Europe
  • Health 2.0 Applications in Emerging Markets
  • Data Analytics: Structuring Information for DecisionMaking
  • Choosing your Digital Health Accelerator
  • Pharma 2.0: Going Beyond the Pill
  • Frontiers of Health 2.0: What's Next?
  • Power to the patient
  • Technology promoting behaviour change and healthy
  • Health 2.0 transforming the daily mission of nurses
  • Who will pay for Health 2.0? An investor's discussion
  • Reimbursement players, trends, criteria and processes
  • SHUSH topics and the famous unmentionables
  • From Health to WellBeing: the rise of wearables and consumer interfaces

For further information and to register, please visit:
https://goo.gl/IVCb3P

Early bird prices end on 18th March. Book you ticket now using the code EHNEWS16 to get 15% discount.

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...